Drug Trial Radar · NCT03779074
Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies
Last checked: Nov 20, 2026Latest source record: Oct 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
918
Actual
Start
Sep 3, 2018
Primary completion
Dec 31, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Kaohsiung Veterans General Hospital.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of H. pylori infection.
Conditions
- Helicobacter Pylori Infection
Interventions
10d bismuth quadruple therapyDrug
rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
14d hybrid therapyDrug
a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days
14D high-dose dual therapyDrug
rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants in Which H. Pylori Was EradicatedTime frame: sixth week after the end of anti- H. pylori therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.